The adoption of robot-assisted Aquablation therapy in NHS and private clinical settings is gaining pace, with recent real-world data demonstrating significant gains in operative efficiency and patient outcomes for men with benign prostatic hyperplasia (BPH).
Aquablation utilizes a high-velocity sterile saline waterjet under robotic control to resect prostate tissue, combining imaging guidance with precision execution. The technology enables consistent treatment across a wide range of prostate sizes and aligns strongly with modern surgical priorities such as shorter theatre time and streamlined throughput.
Recent clinical experience over the past 12 months in NHS practice has shown that Aquablation can be delivered effectively for prostates ranging from approximately 30g up to 280g, without the need for multiple different technologies. Average procedure times have remained competitive — with the majority completed within 60 minutes — even for larger glands.
Importantly, the implementation of this robotic platform has supported enhanced pathways of care, with more than 70% of patients being discharged on the same day following treatment. These findings are consistent with published prospective study data (e.g., WATER, WATER II, WATER III) indicating high clinical success rates and favourable functional outcomes with Aquablation.
The integration of automated procedural tracking also provides valuable clinical intelligence, including prostate size metrics, procedure duration, and workflow data — further supporting quality improvement and surgical planning.
By expanding access to advanced robotic technologies such as Aquablation, urology services within the NHS and private sector are enhancing theatre productivity while maintaining a strong focus on patient-centred care and efficient recovery pathways.
